Wide Ranks

INO

Inovio Pharmaceuticals, Inc.

4.19

Top Statistics
Market Cap 109 M Forward PE -1.12 Revenue Growth -55.40 %
Current Ratio 4.45 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.2300 Enterprise / Revenue 44.62 Price To Sales Trailing12 Months 184.77
Profitability
Profit Margins 0.00 % Operating Margins -32945.87 %
Balance Sheet
Total Cash 110 M Total Cash Per Share 4.25 Total Debt 12 M
Total Debt To Equity 13.42 Current Ratio 4.45 Book Value Per Share 5.15
All Measures
Short Ratio 1122.00 % Message Board Id finmb_28922 Shares Short Prior Month 3 M
Return On Equity -0.9142 City Plymouth Meeting Uuid ac020a93-0ebc-3108-95e6-c7f296b9daee
Previous Close 4.01 First Trade Date Epoch Utc 913 M Book Value 5.15
Beta 0.8330 Total Debt 12 M Volume 319178
Price To Book 0.8139 Last Split Date 1 B Fifty Two Week Low 3.85
Total Cash Per Share 4.25 Total Revenue 591858 Shares Short Previous Month Date 1 B
Target Median Price 10.50 Audit Risk 7 Max Age 86400
Recommendation Mean 2.17 Sand P52 Week Change 0.3133 Operating Margins -32945.87 %
Target Mean Price 10.67 Net Income To Common -121640472 Short Percent Of Float 0.1359
Implied Shares Outstanding 26 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 516230 Average Volume10days 516230 Total Cash 110 M
Next Fiscal Year End 1 B Revenue Per Share 0.0250 Held Percent Insiders 0.0085
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 5 Regular Market Previous Close 4.01 Target Low Price 5.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 5.34 Open 4.08
Free Cashflow -70594784 State PA Dividend Yield 0.00 %
Return On Assets -0.3991 Time Zone Short Name EST Board Risk 4
Trailing Eps -4.43 Day Low 4.08 Address1 660 West Germantown Pike
Shares Outstanding 26 M Compensation Risk 7 Price Hint 4
Target High Price 18.00 Website https://www.inovio.com 52 Week Change -0.1047
Average Volume 339035 Forward Eps -3.71 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 425.00 % Last Split Factor 1:12
Regular Market Day High 4.25 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 13.42 Fifty Two Week High 14.75 Day High 4.25
Shares Short 3 M Regular Market Open 4.08 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 44.62 Revenue Growth -55.40 %
Shares Percent Shares Out 0.1350 Operating Cashflow -112355720 Currency USD
Time Zone Full Name America/New_York Market Cap 109 M Is_nasdaq_100 False
Zip 19462 Quote Type EQUITY Industry Biotechnology
Long Name Inovio Pharmaceuticals, Inc. Overall Risk 6 Regular Market Day Low 4.08
Held Percent Institutions 0.3351 Current Price 4.19 Address2 Suite 110
Enterprise To Ebitda -0.2300 Financial Currency USD Current Ratio 4.45
Industry Disp Biotechnology Number Of Analyst Opinions 6 Country United States
Float Shares 23 M Two Hundred Day Average 8.60 Governance Epoch Date 1 B
Ir Website http://ir.inovio.com/ Price To Sales Trailing12 Months 184.77 Enterprise Value 26 M
Forward PE -1.12 Regular Market Volume 319178 Ebitda -114988248
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.

Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial.

Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.

S.

Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.

The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.